ZNF646

Across TCGA pan-cancer cohorts, ZNF646 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated ZNF646 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ZNF646 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF646 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

LUSC, KICH, and ESCA are the cancer types where ZNF646 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.045	0.798	<.001	18	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
ESCA	DFS	Median	II,III,IV	0.189	0.528	.006	12	view →
UCEC	DFS	Median	All	0.788	0.630	.006	12	view →
SCLC	OS	Median	All	0.301	0.711	.018	9	view →
LGG	OS	Median	All	0.163	0.889	<.001	6	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
SKCM	OS	Median	III,IV	0.223	0.729	<.001	6	view →
KIRP	OS	Median	All	0.111	0.702	.032	3	view →
LUAD	OS	Median	All	0.176	0.670	.039	3	view →
STAD	OS	Median	IV	1.000	0.299	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

ZNF646–LUSC (DFS)

Open the LUSC breakdown →